Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries
Authors' conclusion
Once-daily iGlarLixi provided better glycaemic control with weight benefit and less hypoglycaemia than twice-daily premix BIAsp 30. iGlarLixi may be a favourable alternative to premix BIAsp 30 in people with suboptimally controlled T2D to advance BI therapy in the LATAM region.
Study context
- Population
- Adults with T2D suboptimally controlled with basal insulin plus one or two oral glucose-lowering drugs, HbA1c ≥7.5% to ≤10%, living in Latin American countries (Argentina and Mexico)Argentina and Mexico
- Participants
- 160 adults
- Comparison
- Once-daily iGlarLixi vs twice-daily BIAsp 30
- Primary endpoint
- Non-inferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi vs BIAsp 30
- Follow-up
- 26 weeks
Methodological detailsopen-label, multicentre, 26-week
- Open-label
- Multicentre
- 26-week
Primary result
As reported in the abstract
iGlarLixi vs BIAsp 30Estimate (95% CI)P value
Non-inferiority met (margin 0.3%)
least squares mean difference (HbA1c) −0.47 %(−0.82 to −0.11)
P < 0.001Superiority
least squares mean difference (body weight change) −1.27 %(−2.41 to −0.14)
P = 0.028Non-inferiority margin 0.3 as printed, not drawn
Further findings
| Outcome | P value |
|---|---|
| Superiority for HbA1c reduction | P = 0.010 |
HbA1c <7% without weight gain, and without weight gain and hypoglycaemia
- Greater proportion achieved with iGlarLixi vs BIAsp 30
Safety
ADA Level 1 and 2 hypoglycaemia
- Incidence and rates lower with iGlarLixi vs BIAsp 30
Original publication
Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries. Diabetes Obes Metab. Published 30 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →